🔍

VALIANTLAB - Valiant Laborato

📊 NSE: VALIANTLAB 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 14:53

📢 Recent Corporate Announcements

Valiant Laboratories Q3 Revenue Jumps 55% YoY to ₹54.74 Cr; Net Profit Drops to ₹3.3 Lakhs

🔵 WATCH ⭐ 7/10

EARNINGS 📅 11 Feb 2026, 04:51 PM

Valiant Laboratories reported a strong 55.4% YoY growth in standalone revenue from operations, reaching ₹5,474.42 Lakhs for Q3 FY26. However, net profit for the quarter plummeted to just ₹3.30 Lakhs from ₹160.01 Lakhs in the same period last year, primarily due to a sharp rise in material costs and other expenses. On a nine-month basis, the company showed a significant turnaround, posting a net profit of ₹201.54 Lakhs compared to a loss of ₹538.85 Lakhs in the previous year. The company continues to operate in a single segment of manufacturing chemicals.

Revenue from operations grew 55.4% YoY to ₹5,474.42 Lakhs in Q3 FY26.
Net profit for Q3 FY26 fell sharply to ₹3.30 Lakhs from ₹160.01 Lakhs in Q3 FY25.
9M FY26 revenue doubled to ₹15,173.91 Lakhs compared to ₹7,559.16 Lakhs in 9M FY25.
Company achieved a 9M turnaround with a net profit of ₹201.54 Lakhs vs a loss of ₹538.85 Lakhs YoY.
Total expenses for the quarter rose significantly to ₹5,524.00 Lakhs, severely impacting quarterly margins.

💡 Investors should closely monitor the company's ability to manage rising input costs, as the sharp drop in quarterly profit despite high revenue growth suggests significant margin pressure. While the nine-month turnaround is a positive indicator, the thin quarterly profitability warrants a cautious approach.

Valiant Lab Q3 FY26: Revenue jumps 55% to ₹54.7 Cr; Net Profit collapses to ₹3.3 Lakhs

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 11 Feb 2026, 04:45 PM

Valiant Laboratories reported a significant 55.4% YoY increase in revenue to ₹54.74 crore for Q3 FY26. Despite the strong top-line growth, net profit collapsed to just ₹3.30 lakh, down from ₹1.60 crore in the previous year's quarter. The sharp decline in profitability is attributed to high raw material costs and increased operational expenses which nearly wiped out margins. While the nine-month performance shows a turnaround from a loss to a profit of ₹2.02 crore, the quarterly margin contraction is a major concern.

Revenue from operations increased 55.4% YoY to ₹5,474.42 Lakhs in Q3 FY26.
Net profit crashed 97.9% YoY to ₹3.30 Lakhs from ₹160.01 Lakhs in the year-ago period.
Cost of materials consumed stood at ₹4,015.06 Lakhs, representing approximately 73% of total revenue.
Nine-month net profit turned positive at ₹201.54 Lakhs compared to a loss of ₹538.85 Lakhs in the previous year.
Total expenses for the quarter rose sharply to ₹5,524.00 Lakhs, nearly matching the total income of ₹5,534.93 Lakhs.

💡 Investors should exercise caution as the company is struggling to translate robust revenue growth into bottom-line profits due to severe margin compression. It is advisable to monitor raw material cost trends and operational efficiency in the coming quarters before making new commitments.

Valiant Laboratories Clarifies Single Segment Reporting for Q2 FY26 Results

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 23 Jan 2026, 01:29 PM

Valiant Laboratories has responded to a clarification sought by the National Stock Exchange regarding the absence of segment-wise reporting in its financial results for the quarter ended September 30, 2025. The company clarified that it and its subsidiary operate as an integrated unit within the Paracetamol value chain, with the subsidiary producing key raw materials. Under Ind AS 108, the management views the group as a single operating segment, which is why separate segment details were not provided. The company has committed to including explicit notes regarding this single-segment structure in all future financial filings.

NSE sought clarification on missing segment-wise disclosures for the quarter and half-year ended Sept 30, 2025.
Company operates as an integrated business where the subsidiary produces Acetic Anhydride for the parent's Paracetamol production.
Management confirms the group has only one reportable operating segment under Ind AS 108 guidelines.
The Chief Operating Decision Maker (CODM) reviews performance on a consolidated basis rather than by separate business units.
Valiant Laboratories will include appropriate disclosure notes in subsequent quarters to satisfy regulatory requirements.

💡 This is a routine regulatory clarification regarding reporting standards and does not impact the company's fundamentals. Investors should continue to monitor the core Paracetamol business margins and raw material integration benefits.

Valiant Laboratories Receives ₹12.53 Crore GST Show-Cause Notice

🔴 NEGATIVE ⭐ 7/10

LEGAL 📅 15 Jan 2026, 03:41 PM

Valiant Laboratories Limited has received a Show-Cause Cum Demand Notice from the CGST & Central Excise authorities for an aggregate amount of approximately ₹12.53 Crores. The demand includes ₹9.31 Crores for turnover mismatches during FY 2021-22 and ₹2.85 Crores for allegedly ineligible Input Tax Credit (ITC) on IPO-related expenses. Additionally, the department has raised a demand of ₹36 Lakhs regarding GST on a ₹100 Crore corporate guarantee provided to a related party. The company may also be liable for interest and penalties under the CGST Act, 2017.

Total GST demand of ₹12.53 Crores issued by the Commissioner of CGST & Central Excise (Audit), Raigad.
₹9.31 Crores demand relates to turnover discrepancies between financial statements and GSTR-3B returns for FY 2021-22.
₹2.85 Crores in ITC claimed on IPO expenses deemed ineligible as they relate to exempt supplies (securities).
₹36 Lakhs demand for non-payment of GST on a ₹100 Crore corporate guarantee provided to Valiant Advanced Services Pvt Ltd.
Potential additional financial burden from interest and penalties under Sections 50, 74, and 122 of the CGST Act.

💡 Investors should monitor the company's legal response to this notice and check for any future provisions made in the financial statements. The ₹12.53 Crore demand represents a significant contingent liability that could impact the company's bottom line if the outcome is unfavorable.

Valiant Laboratories Submits Routine SEBI Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 11:20 AM

Valiant Laboratories Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended December 31, 2025. The company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited, confirmed that no requests for dematerialization or rematerialization were received during this period. All securities of the company are already held in dematerialized form, ensuring efficient electronic record-keeping. This is a standard administrative filing required for all listed entities in India.

Quarterly compliance certificate submitted for the period ending December 31, 2025.
Zero requests received for dematerialization, mutilation, or cancellation of securities during the quarter.
100% of the company's securities are confirmed to be held in dematerialized form.
Confirmation provided by Registrar and Share Transfer Agent MUFG Intime India Private Limited.

💡 No action is required from investors as this is a routine regulatory filing confirming standard operational compliance regarding shareholding records.

Valiant Laboratories Receives GST Demand and Penalty of Rs 62.97 Lakhs

🔴 NEGATIVE ⭐ 4/10

REGULATORY 📅 26 Dec 2025, 04:31 PM

Valiant Laboratories Limited has received an order from the CGST & Central Excise authorities for the financial year 2021-22. The order confirms a demand of Rs. 57.25 lakhs due to the incorrect claim of Input Tax Credit (ITC) on capital goods where depreciation was also claimed on the tax component. Including a penalty of Rs. 5.72 lakhs, the total financial impact stands at Rs. 62.97 lakhs. The company is currently reviewing the order and intends to evaluate filing an appeal against the decision.

Total tax demand of Rs. 57,24,953 and penalty of Rs. 5,72,494, aggregating to Rs. 62,97,447
The demand pertains to the wrong availment of ITC on capital goods for FY 2021-22
Alleged violations involve Sections 16(2), 17(5), 73, 50, and 122(2)(a) of the CGST Act, 2017
Company is exploring legal options including filing an appeal with appropriate authorities

💡 Investors should monitor the outcome of the potential appeal process. While the news is negative, the financial impact of Rs 63 lakhs is relatively small compared to the company's overall operations.

Valiant Laboratories Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 12:50 PM

Valiant Laboratories Limited has informed the exchanges that its trading window will be closed starting January 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all designated persons, including directors and promoters. It is scheduled to reopen 48 hours after the official declaration of the financial results.

Trading window closure effective from January 1, 2026
Closure relates to financial results for the period ending December 31, 2025
Applies to Directors, Promoters, and Designated Persons of the company
Window to reopen 48 hours after the announcement of financial results

💡 This is a routine regulatory filing with no direct impact on stock fundamentals. Investors should wait for the announcement of the board meeting date to review the upcoming quarterly performance.

View All VALIANTLAB Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue for the half-year ended September 30, 2025, grew by 130.47% YoY to INR 9,302.52 Lakhs from INR 4,036.33 Lakhs, primarily driven by the Paracetamol API segment.

Profitability Margins

Net Profit Margin (Consolidated) for the 6 months ended September 30, 2025, was 2.17% (INR 202.10 Lakhs profit), a significant recovery from a negative margin in the previous year's corresponding period (INR 525.01 Lakhs loss).

EBITDA Margin

Operating Profit Margin was reported at 1.97% for the period ending September 30, 2025, reflecting tight core profitability due to high material costs.

Capital Expenditure

Capital expenditure for the 6 months ended September 30, 2025, included INR 1,904.24 Lakhs for the purchase of property, plant, and equipment, including capital advances.

Credit Rating & Borrowing

The credit rating was downgraded to 'CRISIL BB+/Stable Issuer not cooperating' from 'CRISIL BBB/Negative'. Finance costs for the 6 months ended September 30, 2025, were INR 20.92 Lakhs.

⚙️ Operational Drivers

Raw Materials

Specific chemical names are not disclosed, but 'Cost of Materials Consumed' represents 83.66% of total revenue (INR 7,783.16 Lakhs).

Capacity Expansion

The company utilized proceeds from a Rights Issue (July 2025) for business objects; current manufacturing is concentrated at the Tarapur, Maharashtra facility.

Raw Material Costs

Raw material costs reached INR 7,783.16 Lakhs for the 6 months ended September 30, 2025, representing 83.66% of revenue, up from 90.06% in the previous year's corresponding period.

📈 Strategic Growth

Growth Strategy

Growth is targeted through the utilization of Rights Issue proceeds (July 2025) to fund business objects and leveraging its established 1980 foundation in specialized Paracetamol API manufacturing.

Products & Services

Paracetamol (Active Pharmaceutical Ingredient).

Brand Portfolio

Valiant Laboratories.

Strategic Alliances

The company operates through its subsidiary, Valiant Advanced Sciences Private Limited.

🌍 External Factors

Industry Trends

The API industry is seeing a shift towards domestic manufacturing in India; Valiant is positioned as a Paracetamol specialist with a long-standing facility in Tarapur, Maharashtra.

Competitive Moat

Durable advantage stems from a long-standing operational history since 1980 and specialized manufacturing scale in Paracetamol API, which is a high-volume essential medicine.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to pharmaceutical manufacturing standards for APIs and SEBI Regulation 29 (Listing Obligations).

Taxation Policy Impact

The effective tax rate for the 6 months ended September 30, 2025, was approximately 36.8% (INR 117.99 Lakhs tax on INR 320.09 Lakhs PBT).

Legal Contingencies

Fines were imposed by BSE and NSE for non-compliance with Regulation 29 of SEBI (LODR) Regulations, 2015, as noted in the November 2025 board comments.